INTRODUCTION
Rab GTPases, the largest family of small guanosine triphosphate (GTP)-binding proteins, regulate multiple steps in eukaryotic vesicle trafficking including vesicle budding, vesicle tethering, and membrane fusion (Hutagalung and Novick, 2011; Pfeffer, 2007; Stenmark, 2009) . In humans, a total of $63 Rab family members are localized to distinct membrane compartments to ensure correct trafficking of different cargos (Pfeffer and Aivazian, 2004) . Rabs function as molecular switches that cycle between GTP-bound ''on'' and guanosine diphosphate (GDP)-bound ''off'' conformational states. Rab-GTP recruits and activates specific downstream effectors. The exchange of GDP for GTP in Rabs is catalyzed by guanine nucleotide exchange factor, whereas GTP hydrolysis is facilitated by GTPase-activating protein (GAP) (Barr and Lambright, 2010; Nottingham and Pfeffer, 2009 ). Most known GAPs for Rab GTPases share a homologous catalytic domain of $200 residues, termed the TBC (Tre-2/Bub2/Cdc16) domain (Barr and Lambright, 2010; Strom et al., 1993) . The TBC domain harbors no sequence similarity to GAPs for Ras and Rho families of GTPases, but similarly employs a conserved arginine residue, termed the arginine finger, to catalyze GTP hydrolysis (Albert et al., 1999; Rak et al., 2000) . Structural studies of yeast Gyp1p reveal a unique catalytic glutamine residue (''glutamine finger'') in the TBCdomain GAPs (Pan et al., 2006) .
Manipulation of Rab GTPase function is often used by intracellular bacterial pathogens to modulate the endocytic and lysosomal pathways, usually for inhibiting phagosome maturation (Brumell and Scidmore, 2007; Salcedo and Holden, 2005) . Shigella flexneri, a causative agent of bacillary dysentery, invades epithelial cells, escapes from the vacuole, resists autophagy-mediated defense, multiplies in the host cytoplasm, and spreads from cell to cell (Ashida et al., 2011) . Critical to many aspects of S. flexneri pathogenesis is a conserved type III secretion apparatus that translocates a handful of effector proteins into host cells. VirA, one of the earliest identified such effectors, is essential for S. flexneri intracellular persistence (Uchiya et al., 1995) . The intracellular survival defects of S. flexneri DvirA mutant can be complemented by the homologous type III effectors EspG and EspG2 from enteropathogenic and enterohaemorrhagic Escherichia coli (EPEC and EHEC) that harbor $20% sequence identity to VirA (Elliott et al., 2001) . VirA was originally proposed to sever host microtubules by using a YopT-like (Shao et al., 2002) cysteine protease activity (Yoshida et al., 2006) , but this view was challenged by recent structural studies (Davis et al., 2008; Germane et al., 2008; Germane and Spiller, 2011; Selyunin et al., 2011) . EPEC is an extracellular pathogen with a pathogenesis life cycle distinct from S. flexneri. EspG is required for bacterial colonization and virulence in a mouse model of EPEC infection (Hardwidge et al., 2005) , but its virulence function in cell culture infection has not been defined. Thus, the molecular mechanism and host target of the VirA/EspG family as well as their roles in Shigella and EPEC infection remain largely unknown.
Here, we discover that both VirA and EspG are indeed GAP proteins that efficiently catalyzes GTP hydrolysis in Rab1, and their expression in host mammalian cells causes disruption of Rab1-mediated ER-to-Golgi trafficking. Crystal structures of VirA/EspG-Rab1-GDP-aluminum fluoride, approximating the GTP-hydrolysis transition-state intermediate, reveal a TBC-like dual-finger catalytic mechanism, but an overall 3D architecture completely different from that of host TBC domain. VirA TBClike GAP activity mediates suppression of host autophagy, contributing to S. flexneri intracellular persistence. Rab1 inactivation by EspG severely blocks host general secretory pathway during EPEC infection, including secretion of interleukin-8 (IL-8).
Crystal structure of the Arf6-EspG-Rab1 ternary complex further demonstrate that EspG is targeted to Arf-containing vesicles and this synthetic pathogenic signaling complex rewires host Arf signaling to Rab1 inactivation.
RESULTS

Identification of TBC-GAP-like Dual-Catalytic-Finger
Motif in the VirA/EspG Family that Are Important for Shigella Intracellular Persistence Expression of VirA is lethal to Saccharomyces cerevisiae (Slagowski et al., 2008) , suggesting a conserved function in the yeast model. Nearly all the residues conserved in VirA, EspG, and EspG2 were mutated individually or in-combination to alanine (Figure S1 available online), and the mutants were each expressed in yeast. Among a total of 46 residues analyzed, three residues (Asp-185, Arg-188, and Gln-280) were found to be required for VirA to block yeast growth ( Figure 1A ). Mutations of any of the other 43 residues, except for a structurally important tyrosine residue (Davis et al., 2008; Germane et al., 2008) , did not affect VirA toxicity in yeast. In S. flexneri-infected mouse embryonic fibroblast (MEF) cells, expression of wild-type VirA in the DvirA strain of S. flexneri could fully rescue the survival defect of the mutant bacteria ( Figure 1B) . Consistent with what was observed in yeast, VirA-RQ mutant (R188K/Q280A) was inactive in supporting intracellular survival of S. flexneri ( Figure 1B ). These analyses establish the importance of Arg-188 and Gln-280 for the physiological function of VirA during S. flexneri infection.
Notably, substitution of Arg-188 even into the related lysine residue completely abolished the yeast toxicity of VirA (Figure 1A) . This reminded us the catalytic arginine finger residue in GAP proteins, which is nonreplaceable by a lysine residue. We then manually inspected the sequence motifs in different classes of GAP proteins and found that Asp-185, Arg-188, Gln-280, and their adjacent sequences in the VirA/EspG family showed a certain degree of similarity to the signature motifs of TBC-domain GAPs for Rab GTPases (Pan et al., 2006) (Figure 1C) . TBC GAP contains a unique glutamine-finger motif (YxQ) in addition to the catalytic arginine-finger motif (IxxDxxR); Arg-188 in 182 VWHDIYR 188 and Gln-280 in 278 FWQ 280 in VirA appeared to feature the two catalytic residues in TBC GAPs (Figure 1C) . Moreover, the aspartate residue in the arginine finger motif in Gyp1p (IxxDxxR) has been shown to be essential for Gyp1p GAP activity (Pan et al., 2006) , and the equivalent Asp-185 in VirA was also found to be required for its cytotoxicity in yeast. These function-directed sequence and structural (see below) analyses implicate that VirA and EspG may function as a GAP for host Rab GTPases.
VirA Harbors a Potent TBC-like GAP Activity that Prefers to Target Rab1 To test the above hypothesis, we investigated the ability of recombinant VirA protein to accelerate GTP hydrolysis. Among a panel of 30 mammalian Rab GTPases assayed, VirA showed a highest GAP activity toward Rab1 ( Figure 1D ). Several other Rabs including Rab6, Rab33, Rab35, and Rab37 could also serve as substrates of VirA with catalytic efficiencies (kcat/Km) ranging from one-twentieth to one-fourth of that on Rab1. VirA displayed no detectable GAP activity on other families of GTPbinding proteins such as RhoA and tubulin (data not shown). The catalytic efficiency of VirA (kcat/Km, 3.18 3 10
on Rab1 is even higher than those of the canonical TBC-domain GAP Gyp1p on Rab1 and Rab33 (Pan et al., 2006) (Figure 2A ). Importantly, the R188K and Q280A mutants of VirA were completely inactive in catalyzing GTP hydrolysis in Rab1 (Figure 2B ). Thus, VirA is a bona fide GAP that prefers to target host Rab1 in vitro.
To establish which Rab is the potential cellular target of VirA, we examined cellular localization of Rabs that showed a relative activity greater than one-sixtieth of that of Rab1, including Rab1, Rab37, Rab30, Rab6, Rab35, Rab38, Rab22, Rab11, Rab19, Rab34, Rab13, and Rab33, in cells expressing VirA or its R188K mutant. Rab1, Rab30, and Rab37 were found to be perfectly colocalized with VirA R188K mutant ( Figures S2A-S2C ), whereas colocalization with other Rabs was either not observed or at least insignificant ( Figures S2D-S2L) . Notably, when wild-type VirA was coexpressed, the localization pattern of Rab1 and only Rab1 underwent a drastic change, from a perinuclear enriched compartment to a completely diffused pattern that lost the colocalization with VirA ( Figure S2A ). This finding indicates an inactivation of cellular Rab1 by the GAP activity of VirA. In contrast to Rab1, Rab30, and Rab37 remained colocalized with wild-type VirA despite that their localizations became slightly fragmented into punctate structures (Figures S2B and S2C) , suggesting that Rab30 and Rab37 are not directly inactivated by VirA. The change of Rab30/Rab37 distribution pattern is probably an indirect consequence of VirA inactivation of other endogenous Rabs, most likely Rab1. Different from the ubiquitous expression of Rab1, Rab37 is a master cell-specific Rab (Masuda et al., 2000) and expression of Rab30 is also largely restricted in the bone marrow-derived haemopoietic system (http://biogps.gnf.org). Genetic inactivation of Ypt1p, the yeast counterpart of Rab1, is lethal to yeast cells (De Antoni et al., 2002) , reminiscent to the effect of VirA expression ( Figure 1A ). These analyses strongly suggest that Rab1 is a preferred target of VirA GAP activity in host epithelial cells.
Rab1 Inactivation by Ectopically Expressed VirA
Disrupts ER-to-Golgi Trafficking Endogenous Rab1 is mainly located at ER exit sites, the preGolgi intermediate compartment as well as the cis-Golgi, and this localization pattern was completely disrupted by VirA expression ( Figure 2C ). Mutation of catalytically important Arg-188 and Gln-280 in VirA (R188K/Q280A) abolished such effects, and the VirA-RQ mutant protein appeared to be highly enriched in Rab1-containing vesicles ( Figure 2C ). Further supporting the identification of Rab1 as the cellular substrate of VirA, coimmunoprecipitation of VirA and wild-type Rab1 could be readily detected in 293T cells ( Figure 2D) ; the Q70L mutation in Rab1 resulted in an enhanced association, whereas the S25N mutant was much attenuated in coprecipitation with VirA. This observation agrees well with that GAP protein targets the GTPbound form of the GTPase. These data together establish that the RabGAP activity of VirA efficiently inactivates Rab1 and disrupts the trafficking of Rab1-containing vesicles in eukaryotic host cells.
We further examined localization of VirA in mammalian cells in comparison with a Golgi marker GFP-PH(FAPP1)-Ub (ubiquitin) (Chen and De Camilli, 2005) and an ER-specific marker calreticulin. Immunostaining of endogenous calreticulin showed a typical ER morphology that apparently did not overlap with the distribution pattern of VirA or VirA-RQ mutant ( Figure S2M ). In contrast, both VirA and VirA-RQ were perfectly colocalized with GFP-PH(FAPP1)-Ub ( Figure S2N ). The Golgi apparatus stained by GFP-PH(FAPP1)-Ub was severely fragmented by the GAP activity of VirA ( Figure S2N ). Further confirming this observation, the cis-Golgi structure stained by GM130, a subunit of a tethering complex on cis-Golgi and also a Rab1 effector (Moyer et al., 2001; Weide et al., 2001) , was found to be completely fragmented by expression of wild-type VirA but not the GAP-inactive VirA-RQ mutant ( Figure 2E ). Localization of VirA was highly enriched in GM130-labeled membrane structure even after the organelle had been disorganized by VirA expression. Consistent with the functional importance of the Golgi for extracellular secretion of secretory proteins, pharmacologically induced secretion of human growth hormone (hGH) (Rivera et al., 2000) was completely blocked in cells expressing wildtype VirA but not the GAP-inactive VirA-RQ mutant ( Figure 2F ). Thus, Rab1 inactivation by the TBC-like GAP activity of VirA blocks ER-to-Golgi trafficking, leading to functional destruction of the cis-Golgi structure in VirA-transfected cells.
VirA Inactivation of Rab1 Counteracts AutophagyMediated Host Defense
Whereas exploring whether disruption of the cis-Golgi structure by VirA plays a role in S. flexneri intracellular survival, we noted that intracellular S. flexneri caused severe Golgi fragmentation in a VirA-independent manner (data not shown), suggesting that the virulence function of VirA is not associated with its activity of disrupting ER-to-Golgi trafficking. One key strategy employed by S. flexneri for intracellular survival is to suppress and escape from autophagy-mediated host defense (Ogawa et al., 2005) . Recent studies have established a role of Rab1 and functional ER exit sites in autophagosome formation (Zoppino et al., 2010) ; in particular, the activity of Rab1 is required for antibacterial autophagy in Salmonella-infected host cells (Huang et al., 2011) . We then examined autophagosome formation associated with S. flexneri DvirA mutant in comparison with the parental wild-type strain. Consistent with that reported previously, wild-type S. flexneri was largely resistant to decoration by GFP-LC3 and could escape from autophagy ( Figure 3A) . In contrast, the DvirA mutant bacteria were often surrounded by GFP-LC3 ( Figure 3A) , which was also positive for the lysosomal marker LAMP-2 ( Figure S3 ). Similar results were obtained when endogenous LC3 was stained by a LC3-specific antibody (data not shown). This suggests that deletion of VirA impairs the ability of the bacteria to counteract autophagy-mediated host defense. Supporting this idea, complementation of the DvirA strain with a plasmid expressing wild-type VirA, but not the GAP-inactive VirA-RQ mutant, reversed bacteria-induced autophagosome and autolysosome formation ( Figure 3A and Figure S3 ). Statistical data showed that loss of VirA TBC-like activity rendered a significant number of more than 20% of infected cells showing autophagosome formation around intracellular S. flexneri (Figure 3B) , which explains the defective intracellular persistence observed with the VirA deletion and GAP activity-deficient mutant S. flexneri ( Figure 1B) . We further investigated whether inhibiting Rab1 activity or disrupting the cis-Golgi structure from the host side could suppress the increased autophagy induced by loss of VirA TBC-like GAP activity. Expression of RFP-Rab1 S25N, the dominant-negative GDP-bound form of Rab1, but not wild-type RFP-Rab1 or RFP alone, completely blocked autophagosome formation around S. flexneri DvirA as well as DvirA complemented with the VirA-RQ mutant ( Figure 3C ). In contrast, cis-Golgi fragmentation induced by RNAi knockdown of GM130 had no effects on S. flexneri DvirA-induced autophagosome formation (data not shown). This result confirms that it is the Rab1 activity but not its function in ER-to-Golgi transport that is required for Rab1 function in antibacterial autophagy (Huang et al., 2011) . Thus, inactivation of Rab1 by VirA TBC-like GAP activity plays an important role in Shigella suppression of host autophagy, thereby contributing to bacterial intracellular survival.
Crystal Structure of VirA-Rab1 Complex Approximating the GTP Hydrolysis Transition-State Intermediate To better understand and define the structural basis for VirA GAP activity, we crystallized the VirA-Rab1-GDP-aluminum fluoride (AlF 3 ) complex and solved the structure to 3.2 Å ( Figure 4A and Table S1 ). AlF 3 is commonly used to stabilize the GDP-bound GTPase in complex with its GAP, which approximates the transition-state intermediate in GTP hydrolysis. The structure of VirA in the Rab1 complex is almost identical to the previously determined apo-structures (Davis et al., 2008; Germane et al., 2008) (Figure S4A ), consisting of well-separated N-terminal and C-terminal domains. In the Rab1-binding C-terminal domain, i.e., the GAP domain, the central six-stranded b sheet is bound by one helix (a4) from the concave surface and seven helices (a5-11) from the convex surface. A large rectangular groove is formed on the convex surface of the GAP domain by a5, a10, the central region of the b sheet, and the linking loops ( Figure 4A and Figure S4B ). The two putative catalytic finger residues Arg-188 (in a5) and Gln-280 (in the linking loop between a9 and a10) are located in the rectangular groove and protrude to bind AlF 3 and GDP ( Figure 4A and Figure S4B ). The rectangular groove in VirA GAP domain provides the surface for contacting substrate Rab1.
Superimposition of VirA-Rab1-GDP-AlF 3 complex structure onto that of Gyp1p-Rab33-GDP-AlF 3 complex (Pan et al., 2006) reveals that Rab1 adopts the same conformation as Rab33 and also uses switch I and II regions for contacting VirA ( Figure 4B ). The rectangular groove-mediated Rab1 binding in VirA also applies to Gyp1p that harbors a similar groove for Rab33 binding ( Figure 4B and Figures S4B and S4C) . Notably, a5 in VirA and aG5 in Gyp1p that supply and position the arginine finger residues are well aligned ( Figure 4B) . Indeed, the two catalytic finger residues Arg-188 and Gln-280 in VirA are located in the same position in the groove and adopt the same conformation as the corresponding Arg-343 and Gln-378 residues in Gyp1p TBC domain.
The stimulated annealing omit map shows a clear electron density for GDP, Mg 2+ , AlF 3 and a putative nucleophilic water ( Figure 4C ), allowing for modeling these ligands in the VirARab1 complex structure ( Figure 4D ). AlF 3 occupies the position of g-phosphate in the GTP-bound state, and its aluminum ion is additionally coordinated by an axial oxygen from GDP as well as the putative nucleophilic water. The guanidine group in Arg-188 has bidentate hydrogen-bonding/ionic interactions with the oxygen from the b-phosphate of GDP and an equatorial fluoride ion ( Figure 4D ). All these chemical features and geometries resemble those observed with other GAP-GTPase-GDP-AlF 3 complexes, including the Gyp1p-Rab33-GDP-AlF 3 complex (Pan et al., 2006; Rittinger et al., 1997; Scheffzek et al., 1997) . In the Gyp1p-Rab33 complex, the catalytic glutamine finger residue mediates bipartite polar interactions with the equatorial fluoride ion and the putative nucleophilic water (Pan et al., 2006) , and this is also the case for Gln-280 in VirA ( Figure 4D ). Also similarly to that in the Gyp1p-Rab33-GDPAlF 3 structure (but different from those in other GTPase-GDP-AlF 3 complexes), Gln-70 in Rab1 does not act as the cis-glutamine residue involved in GTP hydrolysis and instead has hydrogen-bonding interactions with Thr-177 and Asn-180 in VirA. Thus, the conformational and chemical similarities between Arg-188/Gln-280 in VirA and the arginine/glutamine fingers in Gyp1p TBC domain provide the structural basis for VirA TBC-like dual-finger mechanism of catalyzing GTP hydrolysis in Rab1.
Contrasting to the strikingly similar catalytic mechanism and underlying structural basis between VirA and the TBC domain, the a/b-fold GAP domain in VirA exhibits no overall structural similarity to Gyp1p TBC domain that instead is all helical (Figure 4B) . In fact, except for the helix that supplies the arginine finger, no other secondary structural elements can be superimposed from structures of VirA and Gyp1p TBC domain. The Rab1-binding rectangular groove in VirA, compared with that in Gyp1 TBC domain, bears a relatively larger binding interface, within which distinct detailed interactions are involved in contacting the two switch regions in Rab1 ( Figure S4D) . Moreover, the secondary structural contexts for the glutamine finger residue are completely different in VirA and Gyp1 TBC domain. These structural divergences clearly distinguish the bacterial RabGAP from the host TBC-domain RabGAPs despite a similar catalytic mechanism. EspG Exhibits a Similar TBC-like GAP Activity and Disrupts Rab1-Mediated ER-to-Golgi Trafficking EspG/EspG2 only share $20% sequence identity with VirA ( Figure S1 ), but adopts a similar 3D-fold to VirA as revealed by crystal structures of EspG that others (Germane and Spiller, 2011; Selyunin et al., 2011) and we determined ( Figure S5A and Table S1 ). EspG shares the arginine and glutamine finger motifs of VirA ( Figure 1C) , and the two putative catalytic residues (Arg-208 and Gln-293) are structurally equivalent to Arg-188 and Gln-280 in VirA (Figures S5A and S5B) . Purified EspG showed a potent GAP activity toward Rab1 with a catalytic efficiency (kcat/Km, 2.35 3 10 5 M À1 S À1 ) slightly lower than that of VirA on Rab1 (kcat/Km, 3.18 3 10 5 M À1 S À1 ) ( Figure 5A ).
Mutation of either Arg-208 or Gln-293 completely abolished EspG GAP activity ( Figure 5A ). EspG also showed a highest GAP activity toward Rab1 among the panel of 30 mammalian Rabs assayed ( Figure S5C) . Interestingly, the substrate spectrum of EspG appeared to be narrower than that of VirA ( Figure S5C and Figure 1D ). Also, similar to expression of VirA, expression of EspG in mammalian host cells caused severe disruption of the Golgi structure (Clements et al., 2011; Selyunin et al., 2011) , whereas the catalytically inactive EspG-RQ mutant (R208K and Q293A double mutant) was significantly attenuated in causing such effects ( Figure S5D ). Golgi fragmentation induced by EspG was less severe than that by VirA, agreeing with its relative lower GAP activity. EspG expression resulted in disruption of endogenous Rab1 localization, requiring its TBC-like GAP activity ( Figure S5E ). These results suggest that EspG uses a TBC-like GAP activity to interfere with the function of host Rab GTPases in organizing membrane trafficking. Identification of the TBC-like GAP activity of EspG is not only consistent with its high structural homology to VirA but also explains the functional similarity between the two effectors. 
Inactivation of Rab1 by EspG Blocks of the General Secretory Pathway and Inhibits IL-8 Secretion in EPECInfected Cells
We then investigated EspG inactivation of Rab1 and disruption of ER-to-Golgi trafficking in EPEC-infected cells. Immunofluorescence staining showed a largely diffused localization of endogenous Rab1 in EPEC-infected HeLa cells; genetic deletion of both espG and espG2 restored the normal localization pattern of Rab1 ( Figure 5B ). Complementation of the deletion strain with wild-type EspG, but not EspG-RQ mutant, resulted in a Rab1 distribution similar to that observed with wild-type EPEC infection ( Figure 5B ). These demonstrate that that the GAP activity of EspG can also inactivate Rab1and interfere with Rab1-mediated trafficking during bacterial infection. Different from intracellular S. flexneri, EPEC infection by itself did not cause Golgi fragmentation, suggesting that EspG disruption of Rab1-mediated cis-Golgi trafficking might be of functional importance for bacterial virulence. In fact, HeLa cells infected with wild-type EPEC strain showed significantly attenuated hGH reporter secretion; ablation of espG and espG2 resulted in a completely normal hGH release ( Figure 5C ). Expression of wild-type EspG in the deletion strain regained the phenotype of blocking the general secretory pathway, whereas the GAP-inactive EspG-RQ mutant (R208K and Q293A double mutant) failed to do so ( Figure 5C ). Interestingly, expression of wild-type VirA, but not the GAP-inactive VirA-RQ mutant, in espG/espG2 double deletion EPEC strain, also resulted in a rescue effect ( Figure 5C ), providing a further support to the previously observed interchangeable function of VirA and EspG/EspG2 during Shigella infection (Elliott et al., 2001) .
A functional secretory pathway is responsible secretion of many cytokines, chemokines, and antimicrobial peptides that are important for host defense. IL-8 secretion is a hallmark of many enteric bacterial infections including Shigella and EPEC. Consistent with that reported previously, wild-type EPEC infection drastically inhibited IL-8 production upon TNFa stimulation. Notably, deletion of espG and espG2 from EPEC resulted in a significantly higher level (>3-fold) of IL-8 secretion ( Figure 5D ). As EPEC also secretes other effectors to block NF-kB-mediated IL-8 transcription, IL-8 secretion observed with espG/espG2 strain was still lower than that in uninfected cells. Elevated IL-8 secretion in the double deletion strain could be rescued by expression of wild-type EspG but not the GAP-inactive EspG-RQ mutant ( Figure 5D ). These data suggest that the GAP activity of EspG, different from that of VirA in S. flexneri, contributes to suppression of host cytokine secretion as a result of disruption of Rab1-mediated cis-Golgi trafficking. This finding provides one plausible explanation why extracellular pathogens like EPEC have evolved virulence effectors that specifically target host vesicle trafficking pathways.
Structure of EspG-Rab1-GDP-AlF 3 Complex
We also crystallized the EspG-Rab1-GDP-AlF 3 complex and determined the 2.80 Å structure of this transition-statemimicking complex ( Figure 6A and Table S1 ). Structural comparison revealed little conformational changes of EspG upon Rab1 binding ( Figure S6A ). As expected, the EspG-Rab1 complex adopts an overall architecture highly similar to the VirA-Rab1 complex. Superimposition of the two complex structures shows that the corresponding open rectangular groove in EspG binds to Figure 4D . See also Figure S6 .
Rab1 in a VirA-like manner ( Figures S6B and S6C) . A clear electron density for GDP, Mg 2+ , AlF 3 and a putative nucleophilic water was also identified in the stimulated annealing omit map ( Figure 6B ). The putative catalytic finger residues Arg-208 and Gln-293 in EspG, located in equivalent secondary-structure contexts, are engaged in several catalytic interactions with GDP, AlF 3 , and the putative nucleophilic water in an almost identical fashion to those observed with Arg-188 and Gln-280 in the VirA-Rab1-GDP-AlF 3 complex ( Figure 6C ). Thus, EspG is a structural homolog of VirA and its GAP activity employs the same TBC-like dual-finger catalytic mechanism despite the fact that the two effectors appear to impact the virulence of the cognate bacteria in a different way.
Structure of an Arf6-EspG-Rab1Ternary Complex Shows a Synthetic Arf-EspG-Rab1 Signaling Route A recent study identifies small GTPases Arf1/Arf6 as host binding partners of EspG (Selyunin et al., 2011) . The switch I region in Arf6-GTP is mainly responsible for EspG binding and this interaction is required for EspG to cause Golgi disruption in the transfection assay. Our infection assay further established the physiological relevance of this binding as the Arf-binding deficient EspG E392R mutant was unable to complement the deletion strain for disrupting the general secretory pathway ( Figure 5C ), perturbing endogenous Rab1 localization ( Figure 5B ) as well as inhibiting IL-8 secretion (data not shown). We also succeeded in solving a 4.1 Å crystal structure of Arf6-EspG-Rab1 complex ( Figure 7A and Figure S7 ). In the ternary complex, EspG and Rab1 adopt the same conformation and bear a GDP-AlF 3 -mediated interface similar to the binary EspG-Rab1 complex ( Figure 7B ). Meanwhile, the GTP-bound Arf6 contacts a small surface in EspG in a manner similar to that in the previously determined Arf6-EspG complex structure ( Figure 7C ). Notably, EspG rotates about 10 from its position in the binary complex and adopts a slight more open presentation for Rab1 binding in the ternary complex, which results from the conformational flexibility of its Arf6-contacting loops. This structure variation, if not a result of crystal packing, might be of functional significance given that both Rab1 and Arf proteins have constrained presentation with their carboxyl and amino terminus, respectively, anchored to membrane vesicles.
The ternary complex structure clearly demonstrates that EspG uses nonoverlapping surface area to contact Arf6 and Rab1. In fact, Arf6 binding had little effects on the RabGAP activity of EspG in vitro (data not shown). Given that loss of a single Arf protein causes no defects in any step of membrane transport in HeLa cells including ER-to-Golgi trafficking (Volpicelli-Daley et al., 2005) , binding to Arf1/6 likely plays a role in targeting EspG to the right membrane location, where it can physically access Rab1 and catalyze GTP hydrolysis. The two GTPases contact the same side of the EspG molecule, which spatially allows for their lipid-modified termini to be anchored to the same membrane vesicle. Thus, EspG simultaneously hijacks two small GTPases in ER-to-Golgi membrane trafficking with Arf1/6 mainly for membrane targeting and Rab1 for catalytic inactivation, creating a synthetic signaling route of Arf-GTP/EspG/catalytic inactivation of Rab1. This unique mode of action shall be beneficial for the bacteria to secure the disruption of ER-to-Golgi trafficking as EspG binding also prevents Arf from regular nucleotide cycling (Selyunin et al., 2011) .
Given that VirA harbors a largely similar surface region despite the absence of the Arf6-binding residues (Selyunin et al., 2011) , our model suggests a reasonable possibility that VirA might use the same surface to bind Arf1 or another host protein for correct membrane localization. Thus, the VirA/EspG family of bacterial RabGAP is further distinguished from host TBC-domain GAPs in their modes of specific membrane targeting.
DISCUSSION
In this study, we establish that the VirA/EspG family of type III effectors from S. flexneri and EPEC harbors unexpected TBClike RabGAP activities with Rab1 as the preferred host target in vitro and in vivo. For S. flexneri that is largely free-living inside host cytoplasm, inactivation of Rab1 by VirA contributes to bacterial intracellular survival by counteracting autophagy-mediated host defense. The extracellular EPEC exploits the same TBC-like GAP activity of EspG to inactivate Rab1 and block the general secretory pathway, particularly secretion of proinflammatory cytokine IL-8, which can enhance bacterial survival in host animals. Thus, the VirA/EspG family of RabGAP effectors shall stimulate our thinking of a new virulence mechanism of targeting host vesicle trafficking system by diverse pathogens like S. flexneri and EPEC.
The TBC-like GAP Activity Might Be Widely Used in Regulating Membrane Trafficking VirA and EspG share a limited degree of sequence identity, and both proteins bear neither sequence homology nor 3D-fold similarity to eukaryotic TBC-domain GAP. This represents an excellent example of convergent evolution of bacterial virulence stressed by host environment. The TBC-like RabGAP activity of the VirA/EspG family is prone to escape from simple and structural homology searches, particularly when no functional insights are available. Therefore, it is not unexpected that other virulence factors with TBC-like GAP activity might be widely present in bacterial pathogens, particularly those having intracellular life cycle. For example, LepB, a type IV effector from intracellular Legionella pneumophila, has been shown to possess a Rab1-specific GAP activity with an undefined catalytic mechanism (Ingmundson et al., 2007) . It will be interesting to test whether LepB also employs a TBC-like dual-finger catalytic mechanism. Moreover, the possibility also exists that TBC-like RabGAP activity might be used by other unidentified eukaryotic proteins that bear primary sequence and 3D folds different from the ones already known and also defined here.
A Unique Mode of Manipulating Eukaryotic Signaling by EspG and Synthetic Interplay with Host Activities
The mechanism of action of EspG or possibly the VirA/EspG family is also unique in that it targets another Arf GTPase mainly for achieving specific membrane localization, which generates a synthetic pathogenic signaling complex of Arf-EspG-Rab1. Given that EspG specifically recognizes the GTP-bound form of Arf and also because targeting a single Arf protein is unlikely sufficient for disruption of any host function, EspG can be regarded as a unique Arf ''effector'' coming from the bacterial kingdom for pathogenesis, which rewires host Arf signaling to Rab1 inactivation. Interestingly, Gyp1p is also targeted to the Golgi through its N-terminal region-mediated binding to another Rab protein Ypt32p in yeast cells (Rivera-Molina and Novick, 2009) . EspG can interact with GM130, a Rab1 effector (Clements et al., 2011) . If this interaction is not mediated through Rab1, binding to GM130 could potentially serve as another means for EspG to ensure correct membrane targeting. EspG has also been shown to bind to a 12-residue peptide from PAK, and this binding, though promotes the kinase activity of PAK, has no role in EspG disruption of the Golgi structure (Germane and Spiller, 2011; Selyunin et al., 2011) . Interestingly, the PAK peptide occupies part of the Rab1-binding surface in EspG. A possible hypothesis is that PAK binding may serve as a host defense mechanism to counteract the deleterious pathogenic effect of the Arf-EspG-Rab1 complex. Alternatively, PAK might be another host target of EspG, which results in perturbation of other host signaling that remains to be defined.
EXPERIMENTAL PROCEDURES Fluorescence Microscopy and Immunoprecipitation
For fluorescence staining, HeLa cells cultured on coverslips were fixed with 4% paraformaldehyde for 10 min at room temperature (RT), washed with PBS, and then permeabilized for 10 min in PBS containing 0.5% Triton X-100. Cells were then blocked with 1% BSA for 30 min followed by blotting with first and second antibodies for at least 1 hr each. Images were acquired by using a Zeiss LSM510 META laser scanning confocal microscopy. Immunoprecipitation was carried out as previously described (Dong et al., 2010) .
Recombinant Proteins and the GAP Assay E. coli BL21 (DE3) strain (Novagen) was used as the host for all recombinant expression. Protein expression was induced for 16 hr at 16 C or 22 C with
Procedures for detailed description of recombinant protein expression and purification. The GAP assay using the EnzChek Phosphate Assay Kit (Invitrogen) and determination of kinetics were carried out by strictly following the previously described procedure (Pan et al., 2006) . The absorbance at 360 nm was monitored on a UV-2450 spectrometer (Shimadzu).
Crystallization and Data Collection
Rab1-GDP was prepared by adding 10-fold molar excess of GDP into purified Rab1 protein and incubated in a buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM MgCl 2 , and 2 mM DTT for 30 min at RT. VirA was mixed with Rab1-GDP (molar ratio, 1:1) in a buffer containing 50 mM TrisHCl (pH 8.0), 150 mM NaCl, 20 mM NaF, 2 mM AlCl 3 , 5 mM MgCl 2 , and 2 mM DTT, and incubated at 4 C overnight to obtain the VirA-Rab1-GDPAlF 3 complex. The EspG-Rab1-GDP-AlF 3 complex was obtained by using the same method. Both VirA-Rab1 and EspG-Rab1 complexes were concentrated to 20 mg/ml for crystallization. See Extended Experimental Procedures for detailed description of crystallization and data collection of EspG, EspG/ VirA-Rab1 complexes and Arf6-EspG-Rab1 ternary complex.
Structural Determination and Refinement
The VirA-Rab1 complex structure was solved by molecular replacement using VirA (Protein Data Bank [PDB] ID code: 3EB8) and Rab1 (PDB ID code: 2FOL) structures as the searching models. EspG structure was solved by Se-SAD using anomalous diffraction data of Se-Met EspG crystal. The EspG-Rab1 complex structures were solved by molecular replacement by using our native EspG structure and Rab1 model from the VirA-Rab1 complex as the searching models. The Arf6-EspG-Rab1 complex structure was also solved by molecular replacement using our EspG-Rab1 complex and Arf6 structure from EspGArf6 complex (PDB ID code: 3PCR) as the searching models. All structural pictures were drawn in PyMol (http://www.delanoscientific.com/). Statistics of data collection and refinement are listed in Table S1 . See Extended Experimental Procedures for detailed description of structural determination and refinement.
hGH Release and IL-8 Secretion hGH trafficking assay was performed as described previously (Rivera et al., 2000) . See Extended Experimental Procedures for detailed description of the assay protocol. For IL-8 secretion, HeLa cells cultured in 24-well plates were infected with wild-type or indicated derivatives of EPEC E2348/69 for 4 hr and then incubated with fresh medium supplemented with 50 mg/ml gentamicin and 20 ng/ml TNF for 24 hr. The supernatant was collected after centrifugation, and quantification of IL-8 released into the supernatant was performed with an IL-8 ELISA kit (Invitrogen) by following the manufacturer's instruction.
Bacterial Manipulation and Intracellular Persistence Nalidixic acid-resistant S. flexneri 2457T strain and EPEC strain E2348/68 strain were cultured in Tryptic soy broth (TSB) and LB broth, respectively. The DvirA S. flexneri and the DespG/espG2 EPEC strain were constructed by using the suicide vector pCVD442 (Donnenberg and Kaper, 1991) . Intracellular persistence of S. flexneri was assessed as previously described (Elliott et al., 2001) . See Extended Experimental Procedures for detailed description of bacterial manipulation, infection, and intracellular persistence assay.
Shigella-Induced Autophagosome Formation
HeLa cells (3 3 10 4 /well on 24-well plate formats) were transfected with pEGFP-LC3 alone or together with pCS2-RFP, pCS2-RFP-Rab1a, or pCS2-RFP-Rab1a S25N. Eighteen hours later, transfected cells were infected with S. flexneri 2457T wild-type ([WT] pBAD24), DvirA (pBAD24), DvirA (pBAD24-VirA), or DvirA (pBAD24-VirA-RQ) at a MOI of 100. After a 10 min centrifuge (8003 g), infected cells were incubated at 37 C for 1 hr to allow for bacterial invasion and then washed with PBS for three times before fresh medium containing 200 mg/ml of gentamycin was added to kill the extracellular bacteria. Cells were further incubated at 37 C for another 2 hr before being subjected to immunofluorescence staining and confocal laser scanning microscopy analysis. Intracellular bacteria were stained with an anti-Shigella antibody, and the lysosome was marked by anti-LAMP-2 staining.
ACCESSION NUMBERS
Coordinates and structure factors for EspG, the VirA-Rab1-GDP-AlF3 complex, the EspG-Rab1-GDP-AlF3 complex, and Arf6-EspG-Rab1 complex have been deposited with the PDB under the ID codes 4FMA, 4FMB, 4FMC and 4FMD, and 4FME, respectively. 
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